ArticleJournal of neuroendovascular therapy2026
Ruptured Anterior Communicating Artery Aneurysm Associated with von Willebrand Disease Treated Using the Woven EndoBridge Device: An Illustrated Case.
Article in Journal of neuroendovascular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Von Willebrand disease (VWD) is an inherited bleeding disorder caused by quantitative or qualitative deficiencies in von Willebrand factor (VWF). Reports of intracranial aneurysms complicated by VWD, particularly ruptured aneurysms, are rare. Optimal perioperative management during endovascular treatment in this patient group remains unclear. Case Presentation: Here, we report the case of a female in her 50s with type 1 VWD who presented with sudden headache and nausea. Imaging revealed a subarachnoid hemorrhage due to a ruptured anterior communicating artery (Acom) aneurysm. Considering the high risk of surgical bleeding, endovascular therapy was administered. DSA demonstrated a 5.8 × 4.4-mm aneurysm, and a Woven EndoBridge (W-EB) SL device (7 × 3 mm; Terumo Corporation, Tokyo, Japan) was successfully deployed. Periprocedural hemostatic management was performed in consultation with hematology specialists, and a factor VIII/VWF concentrate was administered post-procedure to maintain VWF, which was continued for 3 days post-procedure (intravenous bolus infusions of 2000 units). Antiplatelet therapy was not administered. The postoperative course was uneventful, and no intracranial or access site bleeding occurred. Follow-up angiography on postoperative day 7 revealed thrombus formation within the device and no inflow into the aneurysmal bleb. At 4 months postoperatively, the presence of minor residual flow within the W-EB (Bicêtre Occlusion Scale Score [BOSS] grade 1) was confirmed, and its expected complete occlusion was observed during subsequent follow-ups. Conclusion: This case demonstrates that W-EB placement can be safely performed in patients with VWD and may reduce hemorrhagic risk by avoiding the need for antiplatelet therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.